Jefferies downgraded PTC Therapeutics (PTCT) to Hold from Buy with a price target of $76, down from $91, as the analyst took over coverage of the stock. The story has shifted to the Sephience launch, but the firm awaits progress to ascribe more value for additional indications, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT: